Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-β-treated alloreactive T cells that do not induce graft-versus-host disease

Blood

Volumn 97, Issue 2, 2001, Pages 565-571

  Boussiotis, Vassiliki A ^a   Chen, Zong Ming ^b   Zeller, Jay C ^b   Murphy, William J ^b   Berezovskaya, Alla ^b   Narula, Satwant ^b   Roncarolo, Maria G ^b   Blazar, Bruce R ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CYCLIN A; CYCLIN D3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; GLYCOPROTEIN GP 39; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P27; RAS PROTEIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLOIMMUNITY; ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CLONAL ANERGY; GRAFT VERSUS HOST REACTION; LYMPHOCYTE DIFFERENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE;

EID: 0035863749     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.2.565     Document Type: Article

References (69)

1. In vivo blockade of CD28/CTLA4: BT/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice
2. + T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation
3. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
4. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
5. Transprantation of anergic histoincompatible bone marrow allografts
6. + T cells
7. + T-cell subset inhibits antigen-specific T cell responses and prevents colitis
8. + T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation
9. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation via downregulation of class II major histocompatibility complex
10. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression
11. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role of IL-10 in induction of tolerance
12. Induction of tolerance by IL-10-treated dendritic cells
13. Interleukin-10 inhibits B7 and intacellular adhesion molecule-1 expression on human monocytes
14. A role for nonspecific (cyclosporin A) or specific (monoclonal antibodies to ICAM-1, LFA-1 and IL-10) immunomodulation in the prolongation of skin allografts after antigen-specific pretransplant immunization or transfusion
15. Heart allografts in murine systems: The differential activation of Th2-like effector cells in peripheral tolerance
16. High levels of IL-10 production in vivo are associated with tolerance in SClD patients transplanted with HLA mismatched hematopoietic stem cells
17. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflamatory disease
18. Abrogation of TGFb signaling in T cells leads to spontaneous T celt differentiation and autoimmune disease
19. Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor b1
20. + T cells tolerized ex-vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host lethality capacity but retain normal antigen responses
21. + T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-β
22. Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1
23. D-type cyclin-dependent kinase activity in mammalian cells
24. + T cells
25. + T cells
26. Anergic T-lymphocyte clones have altered inositol phosphate, calcium and tyrosine kinase signaling pathways
27. Induction of the increased fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A
28. Differential association of protein tyrosine kinases with T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation
29. ζ Phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists
30. Partial T cell signaling: Altered phospho-ζ and lack of Zap70 recruitment in APL-induced T cell anergy
31. Defective TCR-mediated signaling in anergic T cells
32. Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways
33. Requirement for the leukocyte-specific adapter protein SLP-76 for normal T cell development
34. Uncoupling of nonreceptor tyrosine kinases from PLC-gamma1 in an SLP-76-deficient T cell
35. Direct interaction of Ras and the aminoterminal region of Raf-1 in vitro
36. GTP-dependent association of Raf-1 with Ha-Ras: Identification of Raf as a target downstream of Ras in mammalian cells
37. ras proteins bind to the amino-terminal regulatory domain of c-Raf-1
38. Activation of Ras as a result of recruitment to the plasma membrane
39. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
40. Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues
41. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74 raf-1
42. ras
43. The regulation and function of p21 ras during T-cell activation and growth
44. Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes
45. Identification of G1 kinase activity for cdk6, a novel cyclin D partner
46. The regulation of p27kip1 expression following the polyclonal activation of murine Go T cells
47. Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein
48. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/cdk4
49. p21 is a universal inhibitor of cyclin kinases
50. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
51. p27kip1 a cyclin-cdk inhibitor, links transforming factor-beta and contact inhibition to cell cycle arrest
52. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity is related to p21
53. Inhibitors of mammalian G1 cyclin-dependent kinases
54. p27kip1 functions as an anergy factor inhibiting IL-2 transcription and clonal expansion of alloreactive human and murine helper T lymphocytes
55. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes
56. cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase and holoenzyme
57. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
58. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21 Cip1
59. TGF-beta 1 pretreatment impairs the allostimulatory function of human bone marrow-derived antigen-presenting cells for both naive and primed T cells
60. G1 phase progression: Cyclin on cue
61. Induction of p27kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway
62. Ras activity in G1 phase required for p27kip1 downregulation, passage through the restriction point and entry into S phase in growth factor-stimulated NIH-3T3 fibroblasts
63. Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells
64. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein
65. Models of T cell anergy: Is there a common molecular mechanism?
66. B7 but not ICAM-1 costimulation prevents the induction of human alloantigen specific tolerance
67. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
68. Mechanisms of disease. Graft-versus-host disease
69. Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin